COVID-19 and Lung Cancer Survival: An Updated Systematic Review and Meta-Analysis

Simple Summary The coronavirus disease (COVID-19) pandemic has increased morbidity and mortality in the general population. Patients with cancer have immune dysfunction due to the use of immunosuppressive agents, poor nutritional status, or the direct effects of the tumor on the reactivity of the immune system, making oncological patients more susceptible to severe disease and death. In this systematic review and meta-analysis, we evaluated whether lung cancer increases the risk of severe COVID-19 and the risk of dying from the disease. We found that mortality in patients with lung cancer was significantly higher than that in control patients (HR = 2.00 [95%CI 1.52, 2.63], p < 0.01) or with other malignancies (HR = 1.91 [95%CI 1.53, 2.39], p < 0.01). In addition, we also observed a higher risk of severe infection in patients with lung cancer (HR = 1.47 [95%CI 1.06, 2.03], p = 0.02). We suggest that, in this setting, vaccine use may be considered a useful and mandatory measure to save lives. Abstract Introduction: The outbreak of COVID-19 poses an unprecedented challenge to global public health. Patients with cancer are at a higher risk during the SARS-CoV-2 pandemic. Patients with lung cancer and COVID-19 were compared to those without cancer and those with other malignancies for the main outcome of this study. The aim of this study was to evaluate the differences in susceptibility, disease severity, and mortality between lung cancer patients and the general population. Methods: Using PRISMA reporting guidelines, we conducted a systematic review and meta-analysis of the published literature. The Cochrane Library database, PubMed, EMBASE, and PubMed Central were comprehensively searched for published papers until 31 May 2022. A pooled risk ratio (OR) with 95% CI was presented as the result of this meta-analysis. Results: We included 29 studies involved 21,257 patients with lung cancer and SARS-CoV-2 infection. Analysis data showed that mortality in patients with lung cancer was significantly higher than that in patients without cancer (HR = 2.00 [95%CI 1.52, 2.63], p < 0.01) or with other malignancies (HR = 1.91 [95%CI 1.53, 2.39], p < 0.01). In addition, we also observed a higher risk of severe infection in terms of life-threatening or required ICU admission/mechanical ventilation for lung cancer patients (HR = 1.47 [95%CI 1.06, 2.03], p = 0.02) than for patients with no cancer or other malignancies. Regarding lung cancer as a risk factor for acquiring SARS-CoV-2 infection, we could not reach statistical significance (hazard ratio [HR] =2.73 [95%CI 0.84, 8.94], p = 0.1). Conclusion: Lung cancer represents an important comorbidity and modifies COVID-19 prognosis in terms of disease severity and mortality. More patients experience severe or even fatal events. Considering their inherent fragility, patients with lung cancer, and generally all oncological populations, should be treated more carefully during the COVID-19 pandemic.

[1]  H. Ellidokuz,et al.  Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients , 2022, Journal of Cancer Research and Clinical Oncology.

[2]  H. Alghamdi,et al.  Recent Chronology of COVID-19 Pandemic , 2022, Frontiers in Public Health.

[3]  C. Chung,et al.  Characterizing cancer and COVID-19 outcomes using electronic health records , 2022, PloS one.

[4]  M. Filetti,et al.  Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer , 2022, European Journal of Cancer.

[5]  S. Nevitt,et al.  Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer , 2022, JAMA network open.

[6]  N. Berger,et al.  Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021 , 2022, JAMA oncology.

[7]  M. Filetti,et al.  Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario , 2022, ESMO Open.

[8]  C. Várnai,et al.  Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19 , 2022, JAMA network open.

[9]  T. Ciuleanu,et al.  Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuţă Oncology Institute series , 2022, ESMO Open.

[10]  M. Piccart,et al.  Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study , 2021, The Lancet Oncology.

[11]  M. Rugge,et al.  SARS-CoV-2 Infection in Cancer Patients: A Population-Based Study , 2021, Frontiers in Oncology.

[12]  A. Dingemans,et al.  Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium , 2021, European Journal of Cancer.

[13]  J. Champ,et al.  Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study , 2021, Cancers.

[14]  V. Rocha,et al.  Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19 , 2021, JCO global oncology.

[15]  Umar Farooque,et al.  Clinical Presentations and Outcomes of Coronavirus Disease 2019 in Patients With Solid Tumors , 2021, Cureus.

[16]  P. Tubert-Bitter,et al.  Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study , 2021, European Respiratory Journal.

[17]  Xiaoqian Jiang,et al.  Factors Associated With COVID-19 Death in the United States: Cohort Study , 2021, JMIR public health and surveillance.

[18]  I. Pavord,et al.  Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study , 2021, The Lancet Respiratory Medicine.

[19]  A. Bernard,et al.  Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level , 2021, Cancers.

[20]  M. Curado,et al.  Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center , 2021, Seminars in Oncology.

[21]  T. Oh,et al.  Impact of coronavirus disease-2019 on chronic respiratory disease in South Korea: an NHIS COVID-19 database cohort study , 2021, BMC Pulmonary Medicine.

[22]  R. Dienstmann,et al.  Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil , 2021, JCO global oncology.

[23]  J. Sohn,et al.  Risk of Coronavirus Disease 2019 Occurrence, Severe Presentation, and Mortality in Patients with Lung Cancer , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[24]  N. Berger,et al.  Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. , 2020, JAMA oncology.

[25]  O. Yazıcı,et al.  Clinical features and outcomes of COVID‐19 in patients with solid tumors: Turkish National Registry Data , 2020, International journal of cancer.

[26]  S. Ristić,et al.  Association between the ACE-I/D polymorphism and nicotine dependence amongst patients with lung cancer. , 2020, Biomedical reports.

[27]  Z. Rao,et al.  Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID‐19: A multicenter study , 2020, Cancer.

[28]  S. Novello,et al.  Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave , 2020, Critical Reviews in Oncology/Hematology.

[29]  G. Dhonneur,et al.  Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients , 2020, JNCI cancer spectrum.

[30]  N. Magné,et al.  Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) , 2020, European Journal of Cancer.

[31]  K. Badani,et al.  Cancer, Mortality, and Acute Kidney Injury among Hospitalized Patients with SARS-CoV-2 Infection , 2020, Asian Pacific journal of cancer prevention : APJCP.

[32]  Min Zhou,et al.  Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis , 2020, BMC cancer.

[33]  Z. Sha,et al.  The impact of the COVID-19 pandemic on lung cancer patients. , 2020, Annals of palliative medicine.

[34]  Y. Murciano-Goroff,et al.  Chemotherapy and COVID-19 Outcomes in Patients With Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Queirolo,et al.  Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19 , 2020, Seminars in Oncology.

[36]  Yongchang Wei,et al.  Prominent Hypercoagulability Associated With Inflammatory State Among Cancer Patients With SARS-CoV-2 Infection , 2020, Frontiers in Oncology.

[37]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[38]  Y. Leng,et al.  Patients With Lung Cancer Have High Susceptibility of COVID-19: A Retrospective Study in Wuhan, China , 2020, Cancer control : journal of the Moffitt Cancer Center.

[39]  J. London,et al.  Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. , 2020, JCO clinical cancer informatics.

[40]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[41]  J. Blay,et al.  High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR , 2020, European Journal of Cancer.

[42]  L. Paz-Ares,et al.  SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death , 2020, European Journal of Cancer.

[43]  A. Addeo,et al.  Cancer and COVID-19: Unmasking their ties , 2020, Cancer Treatment Reviews.

[44]  Yu Hu,et al.  Poor clinical outcomes for patients with cancer during the COVID-19 pandemic , 2020, The Lancet Oncology.

[45]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[46]  G. Dhonneur,et al.  Characteristics and outcome of SARS-CoV-2 infection in cancer patients. , 2020, medRxiv.

[47]  S. Duffy,et al.  Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care , 2020, The Lancet Oncology.

[48]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[49]  T. Zembower.  Epidemiology of Infections in Cancer Patients , 2014, Cancer treatment and research.

[50]  Michelle M. Packard,et al.  Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan , 2005, Human Pathology.

[51]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[52]  V. Stosor,et al.  Infectious complications in cancer patients , 2014 .